The Predictive value of serum glutathione S-transferase (GST-π), P-glycoprotein (PGP), P53, Ki-67 and breast cancer :Systematic review and meta-analysis
serum markers and breast cancer
Abstract
Objective: To evaluate the correlation between triple-negative breast cancer (TNBC) and drug-resistant protein expression, and to provide reference for improving the treatment of TNBC.
Methods: The relevant literature was searched through PubMed, Web of Science, CNKI, WanFang data, along with VIP databases from 2010 to 2024. Literature screening together with data extraction were implemented by two researchers, and literature quality was evaluated. Meta-analysis was implemented on the extracted data by means of RevMan 5.3 software.
Results: There were 7 literatures included, all of which were in English. Meta-analysis results revealed that, compared to non-TNBC, the expression rate of GST-π protein in TNBC was elevated [OR=3.41, 95% CI (2.21, 5.25), P<0.00001], the expression rate of Pgp protein in TNBC was elevated [OR=1.87, 95% CI (1.17, 2.98), P=0.008], the expression rate of P53 protein in TNBC was elevated [OR=3.65, 95% CI (2.25, 5.91), P<0.00001], the expression rate of Ki-67 in TNBC was elevated [OR=1.19, 95% CI (0.54, 1.84), P=0.0004], the expression rate of Topo grade Ⅰ in TNBC was no significance [OR=0.71, 95% CI (0.14, 3.51), P=0.67], the expression rate of Topo grade Ⅱ in TNBC was was no significance [OR=0.56, 95% CI (0.26, 1.21), P=0.14], the expression rate of Topo grade Ⅲ in TNBC was no significance [OR=1.13, 95% CI (0.15, 8.64), P=0.91], the DFS level in TNBC was elevated [OR=0.30, 95% CI (0.15, 0.59), P=0.0005], and the level of OS in TNBC was elevated [OR=0.17, 95% CI (0.11, 0.28), P<0.00001].
Conclusion: There are many drug-resistant proteins in triple-negative breast cancer, which can be more resistant to chemotherapy drugs, so it is necessary to detect drug-resistant proteins during chemotherapy treatment to obtain better clinical treatment effect.
References
2. Talib Hassan, I., et al., The effect of premenstrual tension on academic performance and social interactions among Iraqi medical students. Cell. Mol. Biomed. Rep., 2023. 3(4): p. 205-211.
3. Sasani, S., S. Rashidi Monfared, and A.R. Mirzaei, Identification of some Echinophora platyloba miRNAs using computational methods and the effect of these miRNAs in the expression of TLN2 and ZNF521 genes in different human body organs. Cell. Mol. Biomed. Rep., 2024. 4(1): p. 43-53.
4. Gao, R., et al., Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet, 2016. 48(10): p. 1119-30.
5. Emens, L.A., et al., Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Research, 2015. 75(9_Supplement): p. PD1-6-PD1-6.
6. Lara-Medina, F., et al., Triple-negative breast cancer in Hispanic patients. Cancer, 2011. 117(16): p. 3658-3669.
7. Lawrence, R.T., et al., The proteomic landscape of triple-negative breast cancer. Cell Rep, 2015. 11(4): p. 630-44.
8. Liu, D., et al., EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol, 2012. 29(2): p. 401-5.
9. Li, W., et al., Expression differences of resistance protein in TNBC and NTNBC and the clinical significance. Journal of Modern Medicine & Health, 2014.
10. Wang, W., et al., Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget, 2016. 7(21): p. 31079-87.
11. Zhou, L., et al., Novel prognostic markers for patients with triple-negative breast cancer. Hum Pathol, 2013. 44(10): p. 2180-7.
12. Keam, B., et al., Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 2011. 13(2): p. R22.
13. Huang, L., et al., A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index. PLoS One, 2013. 8(12): p. e83081.
14. Choi, J.J., et al., MRI Findings of Triple Negative Breast Cancer: A Comparison with Non-Triple Negative Breast Cancer. J Korean Soc Magn Reson Med, 2010. 14(2): p. 95-102.
15. Sang, J., et al., Expressions and clinical significance of GST-π, LRP and Topo II in triple negative breast cancer tissues. Chinese Journal of Cancer Prevention and Treatment, 2011. 18(7): p. 521-523.
16. Liu, N.Q., et al., Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst, 2014. 106(2): p. djt376.
17. Foulkes, W.D., I.E. Smith, and J.S. Reis-Filho, Triple-negative breast cancer. N Engl J Med, 2010. 363(20): p. 1938-48.
18. Xuezhang, C., et al., An Epithelial-Mesenchymal Transition-Related LncRNA Signature Predicts Prognosis in Triple-Negative Breast Cancer. Journal of Biological Regulators and Homeostatic Agents, 2023. 37(2): p. 1063-1073.
19. Zhang, Y., et al., Inhibition of P-glycoprotein and glutathione S-transferase-pi mediated resistance by fluoxetine in MCF-7/ADM cells. Biomed Pharmacother, 2013. 67(8): p. 757-62.
20. Tang, S.C., et al., Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. J Pharmacol Exp Ther, 2013. 346(3): p. 486-94.
21. Lee, C.L., et al., Synthesis and biological evaluation of phenanthrenes as cytotoxic agents with pharmacophore modeling and ChemGPS-NP prediction as topo II inhibitors. PLoS One, 2012. 7(5): p. e37897.
Copyright (c) 2025 nuan zhang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.